US2019350898A1PendingUtilityA1

Methods and compositions for treatment of alzheimer's disease

54
Assignee: NEUROTROPE BIOSCIENCE INCPriority: May 18, 2018Filed: May 17, 2019Published: Nov 21, 2019
Est. expiryMay 18, 2038(~11.8 yrs left)· nominal 20-yr term from priority
Inventors:Daniel L. Alkon
A61P 25/28A61K 31/365C07K 14/49A61K 38/00A61K 9/0019
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating Alzheimer's disease comprising administering to a patient in need thereof a pharmaceutically effective amount of bryostatin-1, wherein the patient is not administered a NMDA receptor antagonist. 
     
     
         2 . The method of  claim 1  wherein the NMDA receptor antagonist is memantine. 
     
     
         3 . The method of  claim 1  wherein the patient is diagnosed with moderate Alzheimer's disease. 
     
     
         4 . The method of  claim 1  wherein the patient is diagnosed with moderate to severe Alzheimer's disease. 
     
     
         5 . The method of  claim 1  wherein the patient is administered less than 40 mcg bryostatin-1. 
     
     
         6 . The method of  claim 1  wherein the patient is administered about 15 mcg to about 25 mcg bryostatin-1. 
     
     
         7 . The method of  claim 1  wherein the patient is administered about 20 mcg bryostatin-1. 
     
     
         8 . A method of treating Alzheimer's disease comprising administering to a patient in need thereof a pharmaceutically effective amount of bryostatin-1, wherein the treatment excludes administration of a NMDA receptor antagonist. 
     
     
         9 . The method of  claim 8  wherein the NMDA receptor antagonist is memantine. 
     
     
         10 . The method of  claim 8  wherein the patient is diagnosed with moderate Alzheimer's disease. 
     
     
         11 . The method of  claim 8  wherein the patient is diagnosed with moderate to severe Alzheimer's disease. 
     
     
         12 . The method of  claim 8  wherein the patient is administered less than 40 mcg bryostatin-1. 
     
     
         13 . The method of  claim 8  wherein the patient is administered about 15 mcg to about 25 mcg bryostatin-1. 
     
     
         14 . The method of  claim 8  wherein the patient is administered about 20 mcg bryostatin-1.

Join the waitlist — get patent alerts

Track US2019350898A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.